Press Releases

News Sep 7, 2016 Objective Capital Partners Adds CardioCell to Expanding Portfolio of Life Science Companies SAN DIEGO – Sept. 7, 2016 – Objective Capital Partners, a leading middle market investment bank and mergers and acquisition (M&A) advisory firm focused on transactions for

News Aug 29, 2016 European Society of Cardiology (ESC) Congress Presentation Reveals Results From Pre-Clinical Study Using CardioCell’s Stem Cells for Acute Myocardial Infarction (AMI) ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 29, 2016 – Study sponsor

News Aug 28, 2016 CardioCell Reports Positive Results From the First Phase IIa Clinical Trial Using IV Administration of Stem Cells for Chronic Heart Failure Indications ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 28, 2016 – Study sponsor CardioCell LLC, a

News Aug 28, 2016 European Society of Cardiology (ESC) Congress Poster Session Reveals Results From Pre-Clinical Study Using CardioCell’s Stem Cells for Chronic Ischemic Cardiomyopathy ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 28, 2016 – Study sponsor

News Aug 16, 2016 Three CardioCell-Sponsored Studies Reveal Results at the European Society of Cardiology (ESC) Congress 2016 ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 16, 2016 – CardioCell LLC, a global biotechnology company that uses allogeneic stem cells

News Apr 19, 2016 CardioCell Completes Enrollment for a Phase IIa Clinical Trial Using Its Stem Cells for Participants With Chronic Heart Failure SAN DIEGO — April 19, 2016 — CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular

News Mar 22, 2016 CardioCell Expands Chronic Heart Failure Phase IIa Clinical Trial to MedStar Washington Hospital Center WASHINGTON, D.C — March 22, 2016 — CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications,